{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:26:20Z","timestamp":1776205580027,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or promote metastasis. In this context, an assay able to predict individual responses prior to treatment, including the impact on metastasis would prove of great value to guide treatment options. Here we show that zebrafish xenografts are able to reveal different responses to bevacizumab in just 4 days, evaluating not only individual tumor responses but also the impact on angiogenesis and micrometastasis. Importantly, we perform proof-of-concept experiments where clinical responses in patients were compared with their matching zebrafish Patient-Derived Xenografts\u00a0-\u00a0zAvatars, opening the possibility of using the zebrafish model to screen bevacizumab therapy in a personalized manner.<\/jats:p>","DOI":"10.1038\/s42003-020-1015-0","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T10:03:15Z","timestamp":1591783395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy"],"prefix":"10.1038","volume":"3","author":[{"given":"C\u00e1tia","family":"Rebelo de Almeida","sequence":"first","affiliation":[]},{"given":"Raquel Valente","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Pezzarossa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6852-6023","authenticated-orcid":false,"given":"Joaquim","family":"Gago","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Carvalho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-8308","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Vitor","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Brito","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-3700","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Ribeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"F\u00e1tima","family":"Cardoso","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-7183","authenticated-orcid":false,"given":"Miguel Godinho","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5550-2428","authenticated-orcid":false,"given":"Rita","family":"Fior","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/092986706777585059","volume":"13","author":"G Ranieri","year":"2006","unstructured":"Ranieri, G. et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 13, 1845\u20131857 (2006).","journal-title":"Curr. Med. Chem."},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-011-0202-z","volume":"14","author":"AJ Montero","year":"2012","unstructured":"Montero, A. J., Escobar, M., Lopes, G., Gl\u00fcck, S. & Vogel, C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr. Oncol. Rep. 14, 1\u201311 (2012).","journal-title":"Curr. Oncol. Rep."},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso, F. et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 29, 1634\u20131657 (2018).","journal-title":"Ann. Oncol."},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834010397627","volume":"3","author":"SB Goldfarb","year":"2011","unstructured":"Goldfarb, S. B., Hudis, C. & Dickler, M. N. Bevacizumab in metastatic breast cancer: when may it be used? Ther. Adv. Med. Oncol. 3, 85\u201393 (2011).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"e38364","DOI":"10.1371\/journal.pone.0038364","volume":"7","author":"C Schuster","year":"2012","unstructured":"Schuster, C. et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 7, e38364 (2012).","journal-title":"PLoS ONE"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3892\/ol.2017.6251","volume":"14","author":"KJ Wenger","year":"2017","unstructured":"Wenger, K. J. et al. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol. Lett. 14, 1141\u20131146 (2017).","journal-title":"Oncol. Lett."},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","volume":"42","author":"FALM Eskens","year":"2006","unstructured":"Eskens, F. A. L. M. & Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur. J. Cancer 42, 3127\u20133139 (2006).","journal-title":"Eur. J. Cancer"},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","volume":"20","author":"AA Brandes","year":"2015","unstructured":"Brandes, A. A., Bartolotti, M., Tosoni, A., Poggi, R. & Franceschi, E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20, 166\u2013175 (2015).","journal-title":"Oncologist"},{"key":"1015_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel, H. L. & Mercurio, A. M. VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871\u2013882 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.yexcr.2008.05.004","volume":"314","author":"LS Wanami","year":"2008","unstructured":"Wanami, L. S., Chen, H.-Y., Peir\u00f3, S., Garc\u00eda de Herreros, A. & Bachelder, R. E. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp. Cell Res. 314, 2448\u20132453 (2008).","journal-title":"Exp. Cell Res."},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2010.02.030","volume":"17","author":"P Mak","year":"2010","unstructured":"Mak, P. et al. ERB impedes prostate cancer EMT by destabilizing HIF-a and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell 17, 319\u2013332 (2010).","journal-title":"Cancer Cell"},{"key":"1015_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.01.010","volume":"373","author":"M Luo","year":"2016","unstructured":"Luo, M. et al. VEGF\/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-\u03baB and \u03b2-catenin. Cancer Lett. 373, 1\u201311 (2016).","journal-title":"Cancer Lett."},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","volume":"22","author":"KV Lu","year":"2012","unstructured":"Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex. Cancer Cell 22, 21\u201335 (2012).","journal-title":"Cancer Cell"},{"key":"1015_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592\u2013603 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1015_CR17","first-page":"5412","volume":"59","author":"RM Shaheen","year":"1999","unstructured":"Shaheen, R. M. et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59, 5412\u20135416 (1999).","journal-title":"Cancer Res."},{"key":"1015_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.neo.7900102","volume":"2","author":"JL Rubenstein","year":"2000","unstructured":"Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306\u2013314 (2000).","journal-title":"Neoplasia"},{"key":"1015_CR19","first-page":"4819","volume":"60","author":"J Drevs","year":"2000","unstructured":"Drevs, J. et al. Effects of PTK787\/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819\u20134824 (2000).","journal-title":"Cancer Res."},{"key":"1015_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/B:CLIN.0000024761.00373.55","volume":"21","author":"LS Kim","year":"2004","unstructured":"Kim, L. S., Huang, S., Lu, W., Lev, D. C. & P, J. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 21, 107\u2013118 (2004).","journal-title":"Clin. Exp. Metastasis"},{"key":"1015_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JML Ebos","year":"2009","unstructured":"Ebos, J. M. L. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232\u2013239 (2009).","journal-title":"Cancer Cell"},{"key":"1015_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M P\u00e0ez-Ribes","year":"2009","unstructured":"P\u00e0ez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231 (2009).","journal-title":"Cancer Cell"},{"key":"1015_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.yexcr.2009.11.020","volume":"316","author":"O Gonzalez-Moreno","year":"2010","unstructured":"Gonzalez-Moreno, O. et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp. Cell Res. 316, 554\u2013567 (2010).","journal-title":"Exp. Cell Res."},{"key":"1015_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature10525","volume":"478","author":"B Beck","year":"2011","unstructured":"Beck, B. et al. A vascular niche and a VEGF\u2013Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399\u2013403 (2011).","journal-title":"Nature"},{"key":"1015_CR25","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. 108, 3749\u20133754 (2011).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1015_CR26","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-11-4058","volume":"72","author":"Y Cao","year":"2012","unstructured":"Cao, Y. et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72, 3912\u20133918 (2012).","journal-title":"Cancer Res."},{"key":"1015_CR27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3892\/ijmm.2013.1337","volume":"31","author":"JP Hong","year":"2013","unstructured":"Hong, J. P., Li, X. M., Li, M. X. & Zheng, F. L. VEGF suppresses epithelial-mesenchymal transition by inhibiting the expression of Smad3 and miR-192, a Smad3-dependent microRNA. Int. J. Mol. Med. 31, 1436\u20131442 (2013).","journal-title":"J. Mol. Med."},{"key":"1015_CR28","doi-asserted-by":"publisher","first-page":"38292","DOI":"10.18632\/oncotarget.9438","volume":"7","author":"YR Deng","year":"2016","unstructured":"Deng, Y. R., Liu, W. B., Lian, Z. X., Li, X. & Hou, X. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 7, 38292\u201338305 (2016).","journal-title":"Oncotarget"},{"key":"1015_CR29","doi-asserted-by":"publisher","first-page":"73009","DOI":"10.18632\/oncotarget.20314","volume":"8","author":"HJ Jang","year":"2017","unstructured":"Jang, H. J., Kim, B. J., Kim, J. H. & Kim, H. S. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget 8, 73009\u201373016 (2017).","journal-title":"Oncotarget"},{"key":"1015_CR30","doi-asserted-by":"publisher","unstructured":"Yan, C. et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. Cell (2019). https:\/\/doi.org\/10.1016\/j.cell.2019.04.004.","DOI":"10.1016\/j.cell.2019.04.004"},{"key":"1015_CR31","doi-asserted-by":"publisher","unstructured":"Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. 201618389 (2017). https:\/\/doi.org\/10.1073\/pnas.1618389114.","DOI":"10.1073\/pnas.1618389114"},{"key":"1015_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1242\/dmm.015784","volume":"7","author":"CJ Veinotte","year":"2014","unstructured":"Veinotte, C. J., Dellaire, G. & Berman, J. N. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis. Model. Mech. 7, 745\u2013754 (2014).","journal-title":"Dis. Model. Mech."},{"key":"1015_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10456-006-9040-2","volume":"9","author":"M Haldi","year":"2006","unstructured":"Haldi, M. et al. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9, 139\u2013151 (2006).","journal-title":"Angiogenesis"},{"key":"1015_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-128","volume":"9","author":"IJ Marques","year":"2009","unstructured":"Marques, I. J. et al. Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 9, 128 (2009).","journal-title":"BMC Cancer"},{"key":"1015_CR35","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1242\/jcs.069443","volume":"123","author":"K Stoletov","year":"2010","unstructured":"Stoletov, K. et al. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell Sci. 123, 2332\u20132341 (2010).","journal-title":"J. Cell Sci."},{"key":"1015_CR36","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/0008-5472.CAN-06-4268","volume":"67","author":"S Nicoli","year":"2007","unstructured":"Nicoli, S., Ribatti, D., Cotelli, F. & Presta, M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res. 67, 2927\u20132931 (2007).","journal-title":"Cancer Res."},{"key":"1015_CR37","doi-asserted-by":"crossref","unstructured":"Goishi, K. & Klagsbrun, M. B. Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development. in Developmental vascular biology, 62, 127\u2013152 (Academic Press, 2004).","DOI":"10.1016\/S0070-2153(04)62005-9"},{"key":"1015_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/BD-2010-0307","volume":"32","author":"KJ Chavez","year":"2010","unstructured":"Chavez, K. J., Garimella, S. V. & Lipkowitz, S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35\u201348 (2010).","journal-title":"Breast Dis."},{"key":"1015_CR39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH775>3.0.CO;2-K","volume":"192","author":"RE Hewitt","year":"2000","unstructured":"Hewitt, R. E. et al. Validation of a model of colon cancer progression. J. Pathol. 192, 446\u2013454 (2000).","journal-title":"J. Pathol."},{"key":"1015_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1006\/dbio.2002.0711","volume":"248","author":"ND Lawson","year":"2002","unstructured":"Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307\u2013318 (2002).","journal-title":"Dev. Biol."},{"key":"1015_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1046\/j.1365-2559.2003.01610.x","volume":"42","author":"F Prall","year":"2003","unstructured":"Prall, F., Gringmuth, U., Nizze, H. & Barten, M. Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 42, 482\u2013491 (2003).","journal-title":"Histopathology"},{"key":"1015_CR42","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2559.2005.02160.x","volume":"46","author":"A Couvelard","year":"2005","unstructured":"Couvelard, A. et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 46, 668\u2013676 (2005).","journal-title":"Histopathology"},{"key":"1015_CR43","unstructured":"European Medicines Agency (EMA). Assessment report. EMA\/97237\/2019, Committee for Medicinal Products for Human Use, Vol. 44 (2019)."},{"key":"1015_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10637-014-0129-y","volume":"32","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest. N. Drugs 32, 851\u2013859 (2014).","journal-title":"Invest. N. Drugs"},{"key":"1015_CR45","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.18632\/oncotarget.1671","volume":"5","author":"P M\u00e9sange","year":"2014","unstructured":"M\u00e9sange, P. et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 5, 4709\u20134721 (2014).","journal-title":"Oncotarget"},{"key":"1015_CR46","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.molonc.2014.03.015","volume":"8","author":"I Plantamura","year":"2014","unstructured":"Plantamura, I. et al. PDGFR\u03b2 and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Mol. Oncol. 8, 968\u2013981 (2014).","journal-title":"Mol. Oncol."},{"key":"1015_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417\u2013427 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1015_CR48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ni1007","volume":"4","author":"D Traver","year":"2003","unstructured":"Traver, D. et al. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat. Immunol. 4, 1238\u20131246 (2003).","journal-title":"Nat. Immunol."},{"key":"1015_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen, D. X., Bos, P. D. & Massagu\u00e9, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"1015_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275\u2013292 (2011).","journal-title":"Cell"},{"key":"1015_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"J Elbos","year":"2015","unstructured":"Elbos, J. & Kerbel, R. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis John. Nat. Rev. Clin. Oncol. 8, 210\u2013221 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1015_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.stem.2007.11.002","volume":"2","author":"RM White","year":"2008","unstructured":"White, R. M. et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2, 183\u2013189 (2008).","journal-title":"Cell Stem Cell"},{"key":"1015_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"1015_CR54","unstructured":"Tischer, C. & Tosi, S. Tumor blood vessels_ 3D tubular network analysis. in Bioimage data analysis (ed Miura, K.) Ch. 9 (Wiley, 2016)."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1015-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:16:07Z","timestamp":1670379367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-1015-0","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}